Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14919892 | 0.84 | SCN9A (0.45) | MAP4K4SCN9ACYP2C9CYP3A4SCN1A | |
| SCHEMBL19075514 | 0.83 | SCN9A (0.44) | MAP4K4SCN9ACYP2C9CYP3A4SCN1A | |
| SCHEMBL30828709 | 0.80 | IDO1 (0.50) | SCN9ACYP2C9KMT2A | |
| SCHEMBL481909 | 0.80 | IDO1 (0.50) | SCN9ACYP2C9KMT2A | |
| SCHEMBL15587286 | 0.75 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL16021504 | 0.73 | MEN1 (0.45) | MAP4K4MAPK14MEN1KMT2APIM1 | |
| SCHEMBL20414481 | 0.71 | AHR (0.54) | MAP4K4MEN1KMT2A | |
| SCHEMBL15638204 | 0.71 | MAP4K4 (0.44) | MAP4K4SCN9ACYP2C9LCKCSF1R | |
| SCHEMBL482377 | 0.70 | IDO1 (0.47) | KMT2AAURKB | |
| SCHEMBL29652381 | 0.70 | MAPT (0.50) | MAP4K4CYP3A4LCKCSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | MAP4K4 4072/4885MAPK14 4832/4885SCN9A 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.